On July 9, 2012, ERT announced the acquisition of invivoData. ERT is a global technology-driven provider of health outcomes services to biopharmaceutical sponsors and contract research organizations (CRO). Invivodata is a leading provider of electronic Patient Reported Outcomes (ePRO) solutions and consulting services. The transaction was facilitated by the San Francisco-based private equity group, Genstar Capital, LLC who last week announced that they had completed the acquisition of ERT.
The combined organization will now offer sponsors, CROs and other third-party vendors a combination of market-leading ePRO, Clinical Outcome Assessments (COA), and scientific and regulatory consulting services that is unrivaled in the industry. The invivodata Consulting group bolsters ERT’s position as the scientific thought leader in Health Outcomes Research and complements its market leading position in cardiac safety and respiratory outcomes assessment. The acquisition also enhances ERT’s multi-mode ePRO product portfolio with the introduction of a suite of proven site-based and patient-friendly handheld devices that have already been validated to collect therapy-specific diaries, instruments and assessments.
Crosstree Capital initiated and closed this transaction as exclusive financial advisor to invivodata.